Previous 10 | Next 10 |
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC PR Newswire MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" ...
SUL-DUR is a targeted antibiotic that was specifically designed to treat serious infections caused by Acinetobacter baumannii , including multidrug-resistant and carbapenem-resistant strains, which have been identified by the CDC as an urgent global public health threat. I...
Innoviva press release ( NASDAQ: INVA ): Q3 GAAP EPS of $2.80. Revenue of $67.26M (-31.3% Y/Y). For further details see: Innoviva GAAP EPS of $2.80, revenue of $67.26M
Royalties at $65.6 million in the third quarter of 2022, compared to $65.7 million in the same quarter of 2021, for RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® Announced new $100.0 million share repurchase program Com...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents t...
WALTHAM, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced ...
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced ...
Summary I think the problem of higher revenues and lower profits lingers, and I think there's risk in the recent acquisitions. That written, there is potential here. The problem is that the shares aren't as cheap as I'd like. Thankfully, the options market offers us a way to g...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan S...
Summary Silver Ring Value Partners provides investment advisory services. The Company offers portfolio management, financial planning, and trading services. Silver Ring Value Partners serves investors in the State of Massachusetts. At the end of June 2022 the portfolio was very at...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...